Sickle Cell Disease (SCD) is a genetic blood disorder caused by a mutation in the hemoglobin gene, leading to the production of abnormal hemoglobin S. This results in the formation of crescent-shaped, rigid red blood cells that obstruct blood flow and hinder oxygen delivery to tissues. The disease is characterized by chronic pain, anemia, a higher risk of infections, organ damage, and various severe complications. SCD primarily affects individuals of African, Mediterranean, Middle Eastern, and Indian heritage. Treatment strategies aim to manage symptoms, prevent complications, and improve quality of life through advanced therapies and comprehensive care.

Simplified, visualized, and ready for you—see the infographic!: Click Here

Epidemiological Segmentation of SCD (2020–2034) – 6MM

• Total Prevalence
  
  

• Diagnosed Prevalence
  
  

• Prevalence by SCD Type
  
  

• Number of Treated Cases
  
  

SCD Epidemiology (2023 Insights)
In 2023, approximately 161,000 prevalent cases of Sickle Cell Disease were reported across the six major markets (6MM).

• The United States accounted for about 65% of these cases, reflecting a significant burden.
  
  

• In the U.S., the 18–44 age group had the highest prevalence, indicating the disease’s significant impact on young, working-age individuals.
  
  

SCD Market Overview
The Sickle Cell Disease market across the 6MM was valued at an estimated USD 650 million in 2023.

Market Drivers

• Advancements in gene-editing technologies and disease-modifying therapies are transforming the SCD treatment landscape, offering the possibility of long-term benefits.
  
  

• Increasing awareness, early diagnosis, and growing support from governments and advocacy organizations are contributing to market growth and improving patient access to care.
  
  

Market Challenges

• High treatment costs and limited healthcare infrastructure in low-income regions restrict access to cutting-edge therapies.
  
  

• Regulatory challenges and the complexity of clinical trials may delay the development and approval of new treatments.

Explore key stats, market drivers, and emerging drugs—all in one visual!: Click Here

Promising Emerging Therapies

• Ndec
  
  

• Mitapivat
  
  

• Inclacumab
  
  

• Reni-cel
  
  

• Additional candidates in development
  
  

Key Companies in the SCD Market

• Global Blood Therapeutics
  
  

• Pfizer
  
  

• Agios Pharmaceuticals
  
  

• Editas Medicine
  
  

• Forma Therapeutics
  
  

• Novo Nordisk
  
  

• Bausch Health
  
  

• Bluebird Bio
  
  

• And others

Want more data like this? Get the infographic now!: Click Here